logo
Making these lifestyle changes reduce chronic disease, even if you have a genetic risk

Making these lifestyle changes reduce chronic disease, even if you have a genetic risk

CNN6 days ago
Better health for your whole body can be broken down into just seven factors, according to a new study.
Life's Simple 7 is the American Heart Association's guidelines for achieving and maintaining ideal cardiovascular health. The factors include not smoking, a nutritious diet, regular exercise, a healthy weight, optimal blood pressure, controlled blood sugar and well-managed cholesterol.
Researchers reviewed 483 studies on the impacts of maximizing Life's Simple 7 on the health of many different body systems over the course of people's lives in a meta-analysis published Wednesday in the Journal of the American Heart Association.
Maintaining ideal levels of at least three of Life's Simple 7 metrics was associated with a lower risk of cardiovascular disease, even if someone had a genetic predisposition, according to the data. And better scores across all of the factors showed benefits in many body systems beyond cardiovascular health.
'A few years ago, we learned that heart health and brain health are very closely tied. Through this review, we found that almost every organ system and bodily function also benefits from maintaining the healthy lifestyle behaviors of Life's Simple 7,' said lead study author Dr. Liliana Aguayo, a research assistant professor at the Nell Hodgson Woodruff School of Nursing and the Global Diabetes Research Center at Emory University in Atlanta, in a statement.
'We were pleasantly surprised to find that Life's Simple 7 at optimal levels touched every aspect of health, from head to toe. It goes well beyond just cardiovascular health to encompass whole-body health,' she added.
The researchers conducted a systemic review of studies that followed a gold standard approach, said Dr. Nour Makarem, assistant professor of epidemiology and co-leader of the Chronic Disease Unit at the Columbia University Mailman School of Public Health in New York City. Makarem was not involved in the research.
One of the most significant findings of the research is that a little change makes a big difference when it comes to lifestyle and health, Aguayo said.
The study assessed adherence to Life's Simple 7 using a scale from 0 to 14 points.
Each improvement by 1 point was associated with an 11% decrease in dementia risk, a 6% decreased risk of eye disease, a 23% decreased risk of fatty liver disease, and an 11% decreased risk of chronic kidney disease, Aguayo said.
'This means that small changes, for example, moving from obesity to overweight, adding any physical activity even if below recommended levels counted as progress,' she said.
Many of the studies showed an adherence to Life's Simple 7 was associated with maintaining brain and lung function, vision and hearing, and teeth and muscle strength over the course of aging, according to the data.
The studies included in the meta-analysis used Life's Simple 7 to evaluate lifestyle behaviors, but the AHA has since updated the metrics to Life's Essential 8.
The new guidelines are more comprehensive, such as including avoiding secondhand smoke, vaping and nicotine products in the not smoking factor and pointing people to the Mediterranean diet or DASH diet under the healthy eating metric, Makarem said. DASH stands for Dietary Approaches to Stop Hypertension; high blood pressure is a major contributor to heart disease and stroke.
Importantly, the update added an eighth metric that recognizes the role of sleep in long-term health, he added.
Good sleep means seven to nine hours a night for most adults, 10 to 16 hours for children ages 5 and younger, 9 to 12 hours for kids ages 6 to 12, and 8 to 10 hours for adolescents ages 13 to 18, according to the AHA.
The study confirms that adopting a healthy lifestyle is important to achieve optimal health as well as managing the conventional risk factors for cardiovascular disease –– weight, blood pressure, cholesterol and blood sugar, Aguayo said.
Everyday lifestyle choices have a big impact on overall health, and it's worth it to take steps toward better cardiovascular health, Aguayo said.
'The key message is that it is never too early or too late to make small, feasible changes,' she said in an email. 'Small improvements in diet, physical activity, smoking, or managing risk factors (weight, blood pressure, cholesterol and sugar) can have meaningful benefits, not just for heart health, but for all the body, from head to toe.'
For a heart-healthy diet, Makarem recommends focusing on plant-based foods such as fruits, vegetables, legumes and whole grains and consuming lean proteins such as fish. She also recommended limiting processed foods, sodium and sugar-sweetened beverages.
Adults should engage in 150 minutes of moderate physical activity — like walking, dancing or gardening — or 75 minutes of vigorous physical activity a week, Makarem added.
Even considering how impactful small changes can be, ideal cardiovascular health is very rare –– with less than 4% of people worldwide meeting the criteria, Aguayo said.
'We must do more to support young people, especially women, by making it easier, more affordable, and achievable for all to improve their cardiovascular health,' she added. 'Cardiovascular disease is still the number one killer of women. Supporting the heart health of young people and women is both cost-effective and the right thing to do.'
Sign up for CNN's Fitness, But Better newsletter series. Our seven-part guide will help you ease into a healthy routine, backed by experts.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs
BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs

Yahoo

time12 minutes ago

  • Yahoo

BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs

FRANKLIN LAKES, N.J., July 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologics. The selection of BD Libertas™ Wearable Injector for this pharma-sponsored trial follows successful outcomes from more than 50 BD-conducted pre-clinical and clinical studies, including a device clinical study demonstrating excellent performance with 100% of study participants stating they would likely use the BD Libertas™ Wearable Injector if prescribedi,ii. The pharma-sponsored combination product clinical trial represents a significant advancement in accelerating innovation in drug-device combination products that provide greater flexibility for patients, including potential conversion from infused medications that require patients to travel to a hospital or clinic to more convenient patient care in various settings, including self-injection at home. "This trial demonstrates BD's commitment to helping pharma companies by advancing large-volume injection science, ensuring therapies are accessible and patient friendly by offering more efficient and convenient options for biologics," said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. "BD's enhanced testing capabilities acquired through ZebraSci and the proven capabilities of the BD Libertas™ Wearable Injector technology further position BD as an innovative leader in drug delivery." The BD Libertas™ Wearable Injector is an innovative, prefilled, patient ready-to-use drug delivery systemiii designed to enable delivery of complex biologics via subcutaneous injection. The biologics market is expected to grow to more than $670 billioniv by 2030 and for pharmaceutical companies developing these complex drugs, the BD Libertas™ Wearable Injector offers a customizable, patient-centric solution. The BD Libertas™ Wearable Injector: Supports delivery of high-viscosity biologics (up to 50 centipoise), enabling a wide range of subcutaneous therapies Is offered in 2 to 5 mL and 5 to 10 mL configurations providing flexibility for diverse therapeutic requirements Features a fully mechanical, patient ready-to-use design with a simple "peel, stick and click" mechanism, requiring no end-user filling or assemblyiii BD's ongoing validations of fill-finish and final assembly processes with multiple Contract Manufacturing Organizations (CMOs) enable the company to support pharmaceutical partners from development through commercial-scale production. For more information about how BD Libertas™ Wearable Injector is enabling biologic therapy delivery, visit About BD Libertas™ Wearable InjectorBD Libertas™ Wearable Injector is a product in development; some statements are forward looking and are subject to a variety of risks and uncertainties. BD Libertas™ Wearable Injector is a device component intended for drug-device combination products and not subject to FDA 510(k) clearance or separate EU CE mark certification. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. Contacts: Media: Investors: Fallon McLoughlin Adam Reiffe BD Corporate Communications BD Investor Relations 201.258.0361 201.847.6927 i Early feasibility clinical study of investigational BD Libertas™ Wearable Injector (WI) evaluated 5ml, non- Newtonian ~8cP subcutaneous placebo injections in 52 healthy adult subjects for functionality, tissue effects, subject tolerability (100mm Visual Analog Scale (VAS)) and acceptability (questionnaires with 5-point Likert or yes /no responses). Tissue effects were measured from WI removal post-injection through 24 hours with calipers (wheals) or graded on a 5-point scale (erythema, bleeding) from 0-none to 4-severe, significant, respectively. Where tissue effects were observed, the majority (>50%) were resolved within 60 minutes and all within 24 hours. Subject pain (100mm VAS) peaked mid-injection (mean 9.1mm, SD 13.4) and rapidly resolved within 30 minutes (mean 0 .4mm, SD 2.6). Subjects found acceptable (Likert agree + strongly agree or yes responses) their peak pain (≥90.2%), injection site appearance (≥92.2% ).ii Woodley, W. D. et al. Clinical Evaluation of an Investigational 5ml Wearable Injector in Healthy Human Subjects. Clin Transl Sci. 2021 May;14(3):859-869. Pharma filled and assemblediv Mordor Intelligence (2025). Biologics Market Size - Industry Report on Share, Growth Trends & Forecasts Analysis (2025 - 2030). View original content to download multimedia: SOURCE BD (Becton, Dickinson and Company) Sign in to access your portfolio

U.S. Physical Therapy, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call Dates
U.S. Physical Therapy, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call Dates

Yahoo

time12 minutes ago

  • Yahoo

U.S. Physical Therapy, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call Dates

HOUSTON, July 23, 2025--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced that it will report its financial results for the three months and six months ended June 30, 2025, on Wednesday, August 6, 2025, after the stock market closes, with the conference call to follow the next morning, on Thursday, August 7, 2025. Conference Call Date: Thursday, August 7, 2025 Time: 10:30 am Eastern / 9:30 am Central Dial-In Number: (800) 343-4136 Primary or (203) 518-9843 Alternate Conference ID: USPHQ225 (In order to join this conference call,you will be required to provide the Conference ID listed above) To participate, please call in 15 minutes prior to start time. To listen to the live call, please go to and click on conference calls under the Investor Relations section. Please go to the website 15 minutes early to register, download and install any necessary audio software. If you are unable to listen live, a playback of the conference call can be accessed until November 5, 2025 at USPH's website. About U.S. Physical Therapy, Inc. Founded in 1990, U.S. Physical Therapy, Inc. owns and/or manages 768 outpatient physical therapy clinics in 44 states. USPH clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. USPH also has an industrial injury prevention business which provides onsite services for clients' employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments. More information about U.S. Physical Therapy, Inc. is available at The information included on that website is not incorporated into this press release. View source version on Contacts U.S. Physical Therapy, Hendrickson, Chief Financial OfficerEmail: Chendrickson@ Chris Reading, Chief Executive Officer(713) 297-7000 Three Part AdvisorsJoe Noyons(817) 778-8424

The president vows to slash medication cost to an unachievable degree.
The president vows to slash medication cost to an unachievable degree.

Yahoo

time12 minutes ago

  • Yahoo

The president vows to slash medication cost to an unachievable degree.

President Donald Trump has promised to reduce American drug prices by mathematically impossible figures of up to '1400 percent.' Speaking during a White House event attended by Republican members of Congress and his Cabinet, Trump said he would tackle the long-running issue of high medication costs in the U.S. But Trump did not set any achievable targets for that aim, instead outlining a range of percentages which would yield negative prices, meaning drug companies would have to pay people to take their medications.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store